Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in beneficial interests in the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific share transaction and does not contain financial performance data.
Material Changes
The filing details a specific transaction on July 6, 2011, where Mr. S M Bicknell acquired a beneficial interest in 12 Ordinary shares. This acquisition resulted from the re-investment of dividends under a Personal Equity Plan at a price of 1350.5 pence per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the share transaction in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: July 6, 2011
- Individual: Mr. S M Bicknell
- Shares Acquired: 12 Ordinary shares
- Acquisition Method: Re-investment of dividends via a Personal Equity Plan
- Price per Share: 1350.5 pence
- Notification Date: July 7, 2011